News

Explore the ethical dilemmas of vaccine policy and public trust in health systems as experts discuss the impact of COVID-19 on immunization attitudes.

At SLEEP 2025, Walia discussed findings showing Hispanic individuals may experience more severe cases of sleep disordered breathing compared to the non-Hispanic group.

Phase 3 trial results show FMT was noninferior to standard-of-care vancomycin for patients with a first episode of C diff infection.

At SLEEP 2025, Bruce Corser, MD, discussed promising open-label data on pitolisant’s impact on idiopathic hypersomnia symptoms with HCPLive.

Despite the possibility for enhanced stability of IOL rotation and tilt, the potential for ACD increase and a resulting hyperopic refractive shift warrants caution.

At SLEEP 2025, Winkelman discussed the AASM’s updated guidelines urging clinicians to transition patients with RLS off dopamine agonists due to augmentation risks.

This interview with Andrew Alexis, MD, MPH, highlights his team’s findings in the phase 3b ADmirable trial on lebrikizumab for atopic dermatitis in patients with skin of color.

This interview with Andrew Alexis, MD, MPH, highlights his team’s findings in the phase 3b ADmirable trial on lebrikizumab for atopic dermatitis in patients with skin of color.

This interview with Andrew Alexis, MD, MPH, highlights his team’s findings in the phase 3b ADmirable trial on lebrikizumab for atopic dermatitis in patients with skin of color.

This interview with Andrew Alexis, MD, MPH, highlights his team’s findings in the phase 3b ADmirable trial on lebrikizumab for atopic dermatitis in patients with skin of color.

Findings highlight an increased risk of MASLD, heart failure, type 2 diabetes, and other cardiometabolic diseases following cycles of weight loss and regain.

This June 17, 2025 SOCS News Update highlights creating strategic plans with mentors and mentees.

At SLEEP 2025, Kancherla highlights diagnostic dilemmas, treatment gaps, and the need for pediatric criteria when managing obstructive sleep apnea in teens.

At SLEEP 2025, Kancherla emphasized the importance of using pediatric criteria to manage OSA in adolescents, warning that adult standards may overlook key developmental factors.

The monoclonal antibody garadacimab-gxii offers once-monthly, citrate-free dosing to prevent hereditary angioedema attacks in patients aged ≥ 12 years.

The company believes results from a recent phase 3 chamber trial fulfill the FDA’s requests in the Complete Response Letter received in April of 2025.

The FDA-cleared DermaSensor shows promise for skin cancer detection in primary care.

Recent research comparing the two diseases against a sample of the general population has indicated a substantially higher mortality risk and rate in GPP than in plaque psoriasis.

In this video, the last in a 3-part series, panelists discuss future directions in the field and the importance of multispecialty collaboration.

In this video, part 2 in a 3-part series, panelists discuss clesrovimab's recent approval and gaps in clinician education.

In this video, the first in a 3-part series, panelists discuss recent advancements in RSV management.

These data highlight the adverse events resulting from the use of dutasteride and finasteride in treating androgenetic alopecia.

Study findings highlight a heightened risk of MetS in patients with psoriasis, especially those with more severe disease based on PASI scores.

Research has indicated a suggestive association between predicted psoriasis and uterine corpus cancer in women and prostate cancer in men.

GMRx2 is now the first and only FDA-approved triple combination medication for use as an initial therapy in patients needing multiple drugs to lower blood pressure.

Discover how recent advancements in biologic therapies are transforming asthma and COPD management, emphasizing personalized care and improved patient outcomes.

This interview at RAD 2025 highlights a session on dose flexibility in adult patients with atopic dermatitis, presented by Tejesh Patel, MD.